Cristina Caramés Sánchez

Cristina Caramés Sánchez

Oncología Médica

Titulación

  • Licenciada en Medicina. Universidad de Barcelona 2003-2009.
  • Especialista en Oncología Médica. Hospital Universitario Fundación Jiménez Díaz – Universidad Autonoma de Madrid. 2010-2015

Investigación y docencia

Ensayos clínicos

  • Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor (BELLE-2). Sub Investigator.
  • Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster (HZ/su) Vaccine in Adults With Solid Tumours Receiving Chemotherapy. Sub Investigator
  • A Phase 1b Study to Assess the Safety and Anti-tumour Activity of Dexanabinol Monotherapy and Dexanabinol in Combination with Chemotherapy in Patients with Advanced Tumours. Sub investigator
  • Dose escalation, safety and pharmacokinetic, first in man study, of SAR566658 administered as single agent by intravenous infusion in adult patients with CA6-positive and refractory solid tumors. Sub investigator
  • Phase I Multicenter, Open-label, Clinical and Pharmacokinetic Study of Lurbinectedin (PM01183) in Combination with Capecitabine in Patients with Unresectable Metastatic Breast Cancer (MBC), Pancreatic Cancer (PC) or Metastatic Colorectal Cancer (CRC). Sub investigator
  • Dose escalation, safety and pharmacokinetic, first in man study, of SAR566658 administered as single agent by intravenous infusion in adult patients with CA6-positive and refractory solid tumors. Sub investigator.

Rotación en el IDIBAPS (Instituto de Investigación Sanitaria August Pi i Sunyer) – Hospital clínico de Barcelona. 2007-2008

Rotación en el Centro de Investigación en Salud Internacional de Barcelona (CRESIB). 2009

Programa de Doctorado en la Universidad Autonoma de Madrid 2011-2015

Estancia en "Baylor Research Institute. Gastrointestinal Cancer Department" Septiembre 2014-Enero 2015

Reconocimientos y certificaciones

  • Beca para proyecto de investigación en el Centro de Investigación en Salud Internacional de Barcelona (CRESIB).
  • Beca para rotación en centros de excelencia en el extranjero. Fundación Jiménez Díaz Año 2014

Afiliaciones

  • Sociedad Española de Oncología Médica

Publicaciones

  • Caramés C, Cristóbal I, Moreno V, del Puerto L, Moreno I, Rodriguez M, Marín JP, Correa A V., Hernández R, Zenzola V, Hernández T, León A, Martín JI, Sánchez-Fayos P, García-Olmo D, Rojo F, Goel A, Fernandez-Aceñero MJ, García-Foncillas J. MicroRNA-21 predicts response to preoperative chemoradiotherapy in locally advanced rectal cancer. Int J Colorectal Dis [Internet] 2015;[DOI: 10.1007/s00384-015-2231-9]Available from: http://link.springer.com/10.1007/s00384-015-2231-9Este enlace se abrirá en una ventana nueva
  • Cristobal I, Madoz-Gurpide J, Martin-Aparicio E, Carames C, Aguilera O, Rojo F, Garcia-Foncillas J. Comment on ‘TAp63 suppress metastasis via miR-133b in colon cancer cells’. Br J Cancer [Internet] 2014;111:2369–2369 [DOI: 10.1038/bjc.2014.390]Available from: http://www.nature.com/doifinder/10.1038/bjc.2014.390
  • Del Puerto-Nevado L, Rojo F, Zazo S, Caramés C, Rubio G, Vega R, Chamizo C, Casado V, Martínez-Useros J, Rincón R, Rodríguez-Remírez M, Borrero-Palacios a, Cristóbal I, Madoz-Gúrpide J, Aguilera O, García-Foncillas J. Active angiogenesis in metastatic renal cell carcinoma predicts clinical benefit to sunitinib-based therapy. Br J Cancer [Internet] 2014;110:2700–7 [PMID: 24786599 DOI: 10.1038/bjc.2014.225]Available from: http://www.ncbi.nlm.nih.gov/pubmed/24786599
  • Madoz-Gúrpide J, Zazo S, Chamizo C, Casado V, Caramés C, Gavín E, Cristóbal I, García-Foncillas J, Rojo F. Activation of MET pathway predicts poor outcome to cetuximab in patients with recurrent or metastatic head and neck cancer. J Transl Med [Internet] 2015;13:282 [DOI: 10.1186/s12967-015-0633-7]Available from: http://www.translational-medicine.com/content/13/1/282
  • Cristóbal I, Rincón R, Manso R, Madoz-Gúrpide J, Caramés C, del Puerto-Nevado L, Rojo F, García-Foncillas J. Hyperphosphorylation of PP2A in colorectal cancer and the potential therapeutic value showed by its forskolin-induced dephosphorylation and activation. Biochim Biophys Acta - Mol Basis Dis [Internet] 2014;1842:1823–9 [PMID: 24997451 DOI: 10.1016/j.bbadis.2014.06.032]Available from: http://dx.doi.org/10.1016/j.bbadis.2014.06.032
  • Cristóbal I, Rincón R, Manso R, Caramés C, Aguilera O, Madoz-Gurpide J, Rojo F, García-Foncillas J. Deregulation of miR-200b, miR-200c and miR-429 indicates its potential relevant role in patients with colorectal cancer liver metastasis. J Surg Oncol [Internet] 2014;110:484–5 [DOI: 10.1002/jso.23661]Available from: http://doi.wiley.com/10.1002/jso.23661
  • Cristóbal I, Manso R, Rincón R, Madoz-Gúrpide J, Caramés C, Rojo F, García-Foncillas J. Potential involvement of protein phosphatase 2A in temsirolimus-mediated resensitization to cetuximab in colon cancer cells. J Cancer Res Clin Oncol [Internet] 2014;140:1249–50 [DOI: 10.1007/s00432-014-1707-2]Available from: http://link.springer.com/10.1007/s00432-014-1707-2
  • Cristobal I, Manso R, Rincon R, Carames C, Senin C, Borrero A, Martinez-Useros J, Rodriguez M, Zazo S, Martinez-Aguilera O, Madoz-Gurpide J, Rojo F, Garcia-Foncillas J. PP2A inhibition is a common event in colorectal cancer and its restoration using FTY720 shows promising therapeutic potential. Mol Cancer Ther [Internet] 2014;1535–7163.MCT – 13–0150 – [PMID: 24448818 DOI: 10.1158/1535-7163.MCT-13-0150]Available from: http://mct.aacrjournals.org/content/early/2014/01/21/1535-7163.MCT-13-0150.short
  • Cristóbal I, Manso R, Rincón R, Caramés C, Madoz-Gúrpide J, Rojo F, García-Foncillas J. Up-regulation of c-Cbl suggests its potential role as oncogene in primary colorectal cancer. Int J Colorectal Dis [Internet] 2014;29:641–641 [DOI: 10.1007/s00384-014-1839-5]Available from: http://link.springer.com/10.1007/s00384-014-1839-5
  • Cristóbal I, Caramés C, Madoz-Gúrpide J, Rojo F, Aguilera O, García-Foncillas J. Downregulation of miR-214 is specific of liver metastasis in colorectal cancer and could play a role determining the metastatic niche. Int J Colorectal Dis [Internet] 2014;29:885–885 [DOI: 10.1007/s00384-014-1872-4]Available from: http://link.springer.com/10.1007/s00384-014-1872-4
  • Cristobal I, Rincon R, Manso R, Carames C, Zazo S, Madoz-Gurpide J, Rojo F, Garcia-Foncillas J. Deregulation of the PP2A Inhibitor SET Shows Promising Therapeutic Implications and Determines Poor Clinical Outcome in Patients with Metastatic Colorectal Cancer. Clin Cancer Res [Internet] 2015;21:347–56 [DOI: 10.1158/1078-0432.CCR-14-0724]Available from: http://clincancerres.aacrjournals.org/cgi/doi/10.1158/1078-0432.CCR-14-0724
  • Cristóbal I, Manso R, Rincón R, Caramés C, Zazo S, del Pulgar TG, Cebrián a, Madoz-Gúrpide J, Rojo F, García-Foncillas J. Phosphorylated protein phosphatase 2A determines poor outcome in patients with metastatic colorectal cancer. Br J Cancer [Internet] 2014;111:756–62 [DOI: 10.1038/bjc.2014.376]Available from: http://www.nature.com/doifinder/10.1038/bjc.2014.376

Comunicaciones y ponencias

  • "Sharing experience in the management of colorectal cancer" August 2013. International preceptorships for foreing medical Oncologist group from Saudi Arabian. Fundación Jiménez Díaz, Madrid
  • "Sharing experience in the management of colorectal cancer" October 2013. International preceptorships for foreing medical Oncologist group from Russia. Fundación Jiménez Díaz, Madrid
  • XII Congreso nacional de cirujanos como colaboración en el abordaje multidisciplinar de tumores. Octubre 2012